基于风险与年度乳腺癌筛查:WISDOM随机临床试验
这项平行组、实用性、多中心随机临床试验比较了基于风险的乳腺癌筛查(n=14212)与年度乳腺X线摄影筛查(n=14160),共纳入28372名40至74岁女性。结果显示,基于风险筛查组在≥IIB期癌症发生率上不劣于年度筛查组,但乳腺活检率并未降低,尽管乳腺X线摄影次数更少。
要点
- 基于风险筛查组≥IIB期癌症发生率为30.0/10万 person-years,年度组为48.0/10万 person-years,率差为-18.0/10万 person-years(95%CI,-40.2至4.1)。
- 基于风险筛查组乳腺活检率未低于年度组,率差为98.7/10万 person-years(95%CI,-17.9至215.3)。
- 观察性队列中89%(15980/18031)的参与者选择了基于风险的筛查。
核心结论
- 基于风险的乳腺癌筛查(包括基于人群的基因检测)安全地对风险 and 筛查强度进行了分层,但并未降低活检率。
研究设计与样本
- 平行组、实用性、多中心随机临床试验,比较基于风险筛查(n=14212)与年度筛查(n=14160)。
- 研究对象为40至74岁、无既往乳腺癌或导管原位癌诊断、未行预防性双侧乳房切除术的女性,从美国所有50个州招募,招募时间为2016年9月至2023年2月,随访至2025年9月5日,中位随访5.1年。
- 所有研究程序通过在线平台进行;拒绝随机化的女性纳入观察性队列。
主要发现
- 基于风险筛查组≥IIB期癌症发生率为30.0/10万 person-years(95%CI,16.3-43.8),年度筛查组为48.0/10万 person-years(95%CI,30.1-65.5),率差为-18.0/10万 person-years(95%CI,-40.2至4.1)。
- 基于风险筛查组乳腺活检率未低于年度筛查组,率差为98.7/10万 person-years(95%CI,-17.9至215.3)。
- 基于风险筛查组乳腺X线摄影次数少于年度筛查组,率差为-3835.9/10万 person-years(95%CI,-4516.8至-3154.9)。
- 癌症、活检、乳腺X线摄影和MRI的累积发生率随风险类别升高而增加。
- 在观察性队列中,89%的参与者(15980/18031)选择了基于风险的筛查。
关键数值与推荐
- 最高风险(5年风险≥6%,高外显率致病性变异):每6个月交替进行乳腺X线摄影和磁共振成像(MRI)并提供咨询。
- 升高风险(按年龄风险百分位前2.5%):每年乳腺X线摄影和风险降低咨询。
- 平均风险:每两年乳腺X线摄影。
- 低风险(40-49岁且5年风险<1.3%):不筛查直至风险≥1.3%或年龄50岁。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Individual breast cancer risk can guide screening initiation, frequency, use of supplemental imaging, and preventive measures to improve breast cancer screening by shifting resources from low-risk women to high-risk women. OBJECTIVE: To determine whether risk-based breast cancer screening is a feasible alternative to annual mammography. DESIGN, SETTING, AND PARTICIPANTS: Parallel-group, pragmatic, multicenter randomized clinical trial comparing risk-based (n = 14 212) with annual (n = 14 160) breast cancer screening. Women aged 40 to 74 years without prior diagnoses of breast cancer or ductal carcinoma in situ, or prophylactic bilateral mastectomy, were recruited from all 50 US states from September 2016 to February 2023, with follow-up through September 5, 2025 (median follow-up, 5.1 years). Statistical analysis was conducted between July and November 2025. All study procedures were conducted via an online platform. Women who declined randomization were enrolled in an observational cohort. INTERVENTIONS: Risk assessment included sequencing of 9 susceptibility genes, polygenic risk score, and the Breast Cancer Surveillance Consortium version 2 model. The risk-based group received 1 of 4 recommendations: (1) highest risk (≥6% 5-year risk, high-penetrance pathogenic variant): alternating mammography and magnetic resonance imaging (MRI) every 6 months and counseling; (2) elevated risk (top 2.5 risk percentile by age): annual mammography and risk-reduction counseling; (3) average risk: biennial mammography; and (4) low risk (aged 40-49 years and <1.3% 5-year risk): no screening until risk is 1.3% or greater or age 50 years. MAIN OUTCOMES AND MEASURES: The coprimary outcomes included noninferiority for stage ≥IIB cancers and superiority in reducing biopsy rates. Secondary outcomes included identification of stage ≥IIA cancers, mammogram rates, uptake of prevention strategies in higher risk cohorts, preference for screening group in the observational cohort, ductal carcinoma in situ, MRI, and stage-specific cancer rates. RESULTS: A total of 28 372 women were randomized. The mean (SD) age was 54 (9.6) years and the majority were non-Hispanic White (77%). The rate of stage ≥IIB cancers was noninferior in the risk-based compared with the annual group (risk-based: 30.0 [95% CI, 16.3-43.8] vs annual: 48.0 [95% CI, 30.1-65.5] per 100 000 person-years; rate difference, -18.0 per 100 000 person-years [95% CI, -40.2 to 4.1]). The rate of breast biopsies was not lower in the risk-based group (rate difference, 98.7 per 100 000 person-years [95% CI, -17.9 to 215.3]) despite fewer mammograms (rate difference, -3835.9 [95% CI, -4516.8 to -3154.9]). The cumulative incidence of cancer, biopsy, mammogram, and MRI increased as risk category increased. In the observational cohort, 89% of participants (15 980/18 031) chose risk based. CONCLUSIONS: Risk-based breast cancer screening that includes population-based genetic testing safely stratified risk and screening intensity, but did not reduce biopsy rates. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02620852.
引用
- Esserman LJ, Fiscalini AS, Naeim A, et al. Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial. JAMA. 2026. PMID: 41385349. doi:10.1001/jama.2025.24784
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。